2024-10-11 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc is a leading biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases.

**1. Performance Comparison to S&P 500 (VOO):**

* **REGN's Cumulative Return:** 92.85%
* **VOO's Cumulative Return:** 134.82%
* **Cumulative Return Difference:** -41.1%
* **Relative Divergence:** 34.68% (meaning REGN is currently performing below the S&P 500, but its relative performance sits at 34.68% of its historical range)

**2. Recent Price Movements:**

* **Closing Price:** $1012.19
* **5-Day Moving Average:** $1008.18
* **20-Day Moving Average:** $1074.41
* **60-Day Moving Average:** $1111.03

**3. Technical Indicators:**

* **RSI:** 20.17 (indicating oversold conditions, potential for a rebound)
* **PPO:** -0.63 (indicating bearish momentum, potential for further decline)
* **Delta_Previous_Relative_Divergence:** -28.65 (indicating a recent drop in relative strength compared to the S&P 500)
* **Expected Return:** 0.0% (current estimated 5-year return, compared to S&P 500)

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55B |
| 2024-05-02 | 6.7 | $3.15B |
| 2023-11-02 | 9.48 | $3.36B |
| 2023-08-03 | 9.05 | $3.16B |
| 2024-08-01 | 9.05 | $3.16B |

* **Most Recent Earnings (2024-08-01):**  EPS of $13.25 exceeded analyst expectations, with revenue of $3.55 billion also beating estimates. This suggests strong performance and positive future prospects.

**5. News & Recent Issues:**

* **Recent Market Outlook:**  Regeneron's stock has been under pressure due to concerns about competition in the key therapeutic areas, particularly in ophthalmology.  However, recent strong earnings reports suggest the market may be undervaluing the company's pipeline and future growth potential.
* **Analyst Opinions:** While some analysts remain cautious due to the competitive landscape, others are bullish on Regeneron's long-term prospects based on its robust pipeline and innovation.
* **Performance Highlights:**  Key recent highlights include the approval of several new drugs and continued growth in existing therapies. However, competition in the market remains a significant factor for the company to overcome.

**6. Overall Analysis:**

Regeneron is a company with a strong track record of developing and commercializing innovative drugs, but currently facing headwinds due to competitive pressures. While the stock has underperformed the S&P 500 recently, its strong earnings and positive outlook for future growth suggest potential for a rebound.  Technical indicators point towards oversold conditions, making it a potential buying opportunity for investors with a long-term perspective.

**7. **This analysis should not be considered as financial advice. Investing in stocks always carries inherent risks. Always do your own research and consult with a financial advisor before making any investment decisions.** 
